By DMET genotyping analysis, Hertz et al. described breast cancer patients with higher paclitaxel-related neuropathy risk in the CYP2C8 low-metabolizer group, that carried the CYP2C8*2, *3, or *4 variant. Here, CYP2C8 is linked to neuropathy.